**Interstitial Chemotherapy for Malignant Gliomas**

Ke Sai, Shu‐xin Sun and Zhong‐ping Chen

Additional information is available at the end of the chapter

http://dx.doi.org/10.5772/62838

#### **Abstract**

Glioma is the most common primary tumor in the central nervous system (CNS). Even with aggressive treatments, gliomas remain as one of the most devastating tumors. Chemotherapy through oral administration of temozolomide (TMZ) is currently the standard regimen for malignant gliomas. However, the systemic toxicity and drug resistance are frequently observed in glioma patients. In order to improve the efficacy and minimize side effects, multiple strategies have been developed. Interstitial chemo‐ therapy is a promising one. By directly delivering chemotherapeutic agents in tumor bed, interstitial chemotherapy bypasses the blood–brain barrier (BBB) and therefore achieves a higher concentration with less systemic exposure. In this chapter, we will have a thorough review on the development and the application of interstitial chemotherapy in gliomas, with the focus on the biomaterial‐based and convection‐enhanced delivery system. In addition, the future of interstitial chemotherapy is also be shortly discussed.

**Keywords:** malignant gliomas, local therapy, surgery, adjuvant chemotherapy, temo‐ zolomide, Gliadel waffer
